Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?

G. Papa, S. Tura, F. Mandelli, M. L. Vegna, D. Defazio, P. Mazza, P. L. Zinzani, R. Simoni, O. DePita, G. Ferranti, P. L. Ghetti, D. Criscuolo

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

This study was designed to evaluate the therapeutic efficacy and toxicity of recombinant interferon alpha-2a (rIFN alfa-2a) given as initial systemic therapy in untreated mycosis fungoides and/or Sezary's syndrome patients, at a slowly escalating schedule up to the maximal tolerated dose. At the same time this schedule was administered in patients who had relapsed or were refractory to previous treatment: 28 newly diagnosed and 15 previously treated patients entered the study. IFN was given daily with dose escalation from 3 to 18 MU. The last follow-up in June 1990 indicates that 90% of previously untreated patients who obtained a complete remission remain in continuous complete remission after 18 to 40 months and that 75% of previously untreated patients who obtained partial remission remain in partial remission after 20-44 months. The event-free survival projected, calculated using the Kaplan and Meier product limit technique, was 21% of all patients at 54.7 months (40% in the previously untreated groups and 14% in the previously treated group: P = 0.12). In conclusion, interferon is very effective as a single agent in cutaneous T-cell lymphomas.

Original languageEnglish
Pages (from-to)48-51
Number of pages4
JournalBritish Journal of Haematology, Supplement
Volume79
Issue number1
Publication statusPublished - 1991

Fingerprint

Cutaneous T-Cell Lymphoma
Interferon-alpha
Appointments and Schedules
Therapeutics
Sezary Syndrome
Mycosis Fungoides
Maximum Tolerated Dose
Interferons
Disease-Free Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Papa, G., Tura, S., Mandelli, F., Vegna, M. L., Defazio, D., Mazza, P., ... Criscuolo, D. (1991). Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? British Journal of Haematology, Supplement, 79(1), 48-51.

Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? / Papa, G.; Tura, S.; Mandelli, F.; Vegna, M. L.; Defazio, D.; Mazza, P.; Zinzani, P. L.; Simoni, R.; DePita, O.; Ferranti, G.; Ghetti, P. L.; Criscuolo, D.

In: British Journal of Haematology, Supplement, Vol. 79, No. 1, 1991, p. 48-51.

Research output: Contribution to journalArticle

Papa, G, Tura, S, Mandelli, F, Vegna, ML, Defazio, D, Mazza, P, Zinzani, PL, Simoni, R, DePita, O, Ferranti, G, Ghetti, PL & Criscuolo, D 1991, 'Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?', British Journal of Haematology, Supplement, vol. 79, no. 1, pp. 48-51.
Papa G, Tura S, Mandelli F, Vegna ML, Defazio D, Mazza P et al. Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? British Journal of Haematology, Supplement. 1991;79(1):48-51.
Papa, G. ; Tura, S. ; Mandelli, F. ; Vegna, M. L. ; Defazio, D. ; Mazza, P. ; Zinzani, P. L. ; Simoni, R. ; DePita, O. ; Ferranti, G. ; Ghetti, P. L. ; Criscuolo, D. / Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?. In: British Journal of Haematology, Supplement. 1991 ; Vol. 79, No. 1. pp. 48-51.
@article{d24f97df95404512a49d5daa167b9e3f,
title = "Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?",
abstract = "This study was designed to evaluate the therapeutic efficacy and toxicity of recombinant interferon alpha-2a (rIFN alfa-2a) given as initial systemic therapy in untreated mycosis fungoides and/or Sezary's syndrome patients, at a slowly escalating schedule up to the maximal tolerated dose. At the same time this schedule was administered in patients who had relapsed or were refractory to previous treatment: 28 newly diagnosed and 15 previously treated patients entered the study. IFN was given daily with dose escalation from 3 to 18 MU. The last follow-up in June 1990 indicates that 90{\%} of previously untreated patients who obtained a complete remission remain in continuous complete remission after 18 to 40 months and that 75{\%} of previously untreated patients who obtained partial remission remain in partial remission after 20-44 months. The event-free survival projected, calculated using the Kaplan and Meier product limit technique, was 21{\%} of all patients at 54.7 months (40{\%} in the previously untreated groups and 14{\%} in the previously treated group: P = 0.12). In conclusion, interferon is very effective as a single agent in cutaneous T-cell lymphomas.",
author = "G. Papa and S. Tura and F. Mandelli and Vegna, {M. L.} and D. Defazio and P. Mazza and Zinzani, {P. L.} and R. Simoni and O. DePita and G. Ferranti and Ghetti, {P. L.} and D. Criscuolo",
year = "1991",
language = "English",
volume = "79",
pages = "48--51",
journal = "British Journal of Haematology, Supplement",
issn = "0963-1860",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?

AU - Papa, G.

AU - Tura, S.

AU - Mandelli, F.

AU - Vegna, M. L.

AU - Defazio, D.

AU - Mazza, P.

AU - Zinzani, P. L.

AU - Simoni, R.

AU - DePita, O.

AU - Ferranti, G.

AU - Ghetti, P. L.

AU - Criscuolo, D.

PY - 1991

Y1 - 1991

N2 - This study was designed to evaluate the therapeutic efficacy and toxicity of recombinant interferon alpha-2a (rIFN alfa-2a) given as initial systemic therapy in untreated mycosis fungoides and/or Sezary's syndrome patients, at a slowly escalating schedule up to the maximal tolerated dose. At the same time this schedule was administered in patients who had relapsed or were refractory to previous treatment: 28 newly diagnosed and 15 previously treated patients entered the study. IFN was given daily with dose escalation from 3 to 18 MU. The last follow-up in June 1990 indicates that 90% of previously untreated patients who obtained a complete remission remain in continuous complete remission after 18 to 40 months and that 75% of previously untreated patients who obtained partial remission remain in partial remission after 20-44 months. The event-free survival projected, calculated using the Kaplan and Meier product limit technique, was 21% of all patients at 54.7 months (40% in the previously untreated groups and 14% in the previously treated group: P = 0.12). In conclusion, interferon is very effective as a single agent in cutaneous T-cell lymphomas.

AB - This study was designed to evaluate the therapeutic efficacy and toxicity of recombinant interferon alpha-2a (rIFN alfa-2a) given as initial systemic therapy in untreated mycosis fungoides and/or Sezary's syndrome patients, at a slowly escalating schedule up to the maximal tolerated dose. At the same time this schedule was administered in patients who had relapsed or were refractory to previous treatment: 28 newly diagnosed and 15 previously treated patients entered the study. IFN was given daily with dose escalation from 3 to 18 MU. The last follow-up in June 1990 indicates that 90% of previously untreated patients who obtained a complete remission remain in continuous complete remission after 18 to 40 months and that 75% of previously untreated patients who obtained partial remission remain in partial remission after 20-44 months. The event-free survival projected, calculated using the Kaplan and Meier product limit technique, was 21% of all patients at 54.7 months (40% in the previously untreated groups and 14% in the previously treated group: P = 0.12). In conclusion, interferon is very effective as a single agent in cutaneous T-cell lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=0025937507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025937507&partnerID=8YFLogxK

M3 - Article

C2 - 1931709

AN - SCOPUS:0025937507

VL - 79

SP - 48

EP - 51

JO - British Journal of Haematology, Supplement

JF - British Journal of Haematology, Supplement

SN - 0963-1860

IS - 1

ER -